Zimmer Biomet Holdings, Inc. (ZBH)

Orthopedic implants, 41% in the U.S. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 20, 2026. Ranked 67 of the 95 Healthcare companies read so far, by the share within reach now.

The filing states 17,000 employees, 7,000 in the U.S., with 6,000 in manufacturing and 2,000 in research, all for orthopedic and surgical products.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 32% at the end of 2027, 37% at the end of 2028, 39% at the end of 2030. By the patterns, the work is about 40% desk work, 16% people work and 45% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 56% of the working time stays with people (conversation, in-person and hands-on work), 35% becomes checking a model's work and 6% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

17,000 employees as of December 31, 2025 (stated). Approximately 7,000 of 17,000 employees are in the U.S. (41%) and 10,000 outside, primarily in Europe, Japan and China.

The filing: “As of December 31, 2025, we employed approximately 17,000 employees worldwide, including approximately 2,000 employees dedicated to research and development.”

The workforce as industry patterns

What the filing says about the workforce: 2,000 in research and development and 6,000 in manufacturing; 7,000 in the U.S. and 10,000 outside; employee resource group membership about 15% of the workforce; total recordable incident rate 0.22 and lost time rate 0.10 in 2025.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Medical Equipment and Supplies Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Abbott Laboratories (ABT, 115,000 employees)18% now, 35% by 2028
• Becton, Dickinson and Company (BDX, 72,000 employees)19% now, 36% by 2028
• Boston Scientific Corporation (BSX, 59,000 employees)19% now, 42% by 2028
• Stryker Corporation (SYK, 56,000 employees)19% now, 39% by 2028
• Baxter International Inc. (BAX, 37,500 employees)19% now, 37% by 2028
• Align Technology, Inc. (ALGN, 20,290 employees)19% now, 36% by 2028
• Solventum Corporation (SOLV, 20,000 employees)20% now, 43% by 2028
• STERIS plc (STE, 17,937 employees)22% now, 39% by 2028

What the filing says about AI

11 sentences in the filing name AI. Eleven sentences: the company's digital and robotic technologies leverage data analytics and artificial intelligence, it is exploring AI and machine learning in multiple areas, and new products with AI and software as a medical device fall under emerging FDA oversight.

• “We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic ("CMFT") products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.”
• “We are broadening our offerings in certain of our product categories and exploring new technologies, including artificial intelligence and machine learning, with possible applications in multiple areas.”
• “Additionally, certain of our new products incorporate innovations related to artificial intelligence, machine learning and software as a medical device, which are subject to emerging FDA oversight and regulation.”
• “We are also subject to emerging regulations, directives, voluntary commitments and guidance governing data security and cyber risk management for medical devices as well as emerging regulations, directives, voluntary commitments and guidance relating to artificial intelligence.”
• “Further, our use of artificial intelligence and machine learning in our infrastructure and products exposes us to a variety of threats, risks and uncertainties, including with respect to changing laws and regulations regarding the use of such technologies; the risks of inaccuracies, errors and interruptions affecting business processes supported by artificial intelligence; the risks of inaccura...”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20213median 0
• Fiscal 20226median 0
• Fiscal 202310median 1
• Fiscal 202411median 4
• Fiscal 202511median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The manufacturing (6,000) and R&D (2,000) counts are stated; the other 9,000 in sales, distribution and administration are read inside the device pattern by description (c).

Source: the company's annual report on EDGAR, accession 0001193125-26-059853, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.